Board of Directors

John D. Diekman, Ph.D.

Chairman of the Board | Founding Partner, 5AM Ventures

John D. Diekman, Ph.D. is a Founding Partner of 5AM Ventures. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. Dr. Diekman currently serves as Chairman of IDEAYA as well as on the Boards of Igenica and Wildcat. He is a Charter Trustee of Princeton University and a former Trustee of the California Institute of Technology and of the Scripps Research Institute, where he served as Chairman. He serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman holds an Honorary Degree of Doctor of Laws from Monash University.

Timothy Shannon, M.D.

Director | General Partner, Canaan Partners

Timothy Shannon, M.D., is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at NextCure, Vivace, and CytomX (CTMX, IPO 2015). Prior successful companies include Civitas Theraputics (acquired by Acorda) and Novira Therapeutics (acquired by Johnson & Johnson). Dr. Shannon previously was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company. CuraGen merged with Celldex Therapeutics in 2009 where Dr. Shannon served on the board. Prior to that he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Dr. Shannon began his career as an assistant professor of pulmonary and critical care medicine at Yale University School of Medicine, received his M.D. from the University of Connecticut, and his B.A. from Amherst College.

Terry Rosen, Ph.D.

Director | Chief Executive Officer, Arcus Biosciences

Terry Rosen, Ph.D. is currently the CEO of Arcus Biosciences. He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015. Prior to co-founding Flexus in October of 2013, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. He holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley.

Jeffrey Stein, Ph.D.

Director | President and Chief Executive Officer, Cidara Therapeutics

Jeffrey Stein, Ph.D., has been the President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.

Thilo Schroeder, Ph.D.

Director | Partner at Nextech Invest

Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

Scott Morrison

Director | Partner, Ernst & Young (retired)

Mr. Morrison has served as a member of IDEAYA’s board of directors since July 2018. He had a 35-year career in public accounting, serving public and private companies in the life sciences sector. Mr. Morrison was a partner at Ernst & Young LLP and served as its U.S. Life Sciences Leader until his retirement in 2015. He has worked on hundreds of public and private financings, M&A transactions and corporate collaborations. Mr. Morrison currently serves on the board of directors and chairs the audit committees of Audentes Therapeutics, Corvus Pharmaceuticals, Global Blood Therapeutics and Symic Bio. He has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison holds a B.S. in business administration from the University of California, Berkeley. He is a certified public accountant (inactive).

Yujiro S. Hata

Director | Chief Executive Officer, IDEAYA Biosciences

Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In August 2015, he launched IDEAYA Biosciences as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences and FLX Bio, which he led through its acquisition by Bristol-Myers Squibb in April 2015. From 2010 through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Business Development, Senior Vice President, Business Development, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation by the U.S. FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.

Yujiro obtained his M.B.A. at the University of Pennsylvania, his B.A. in chemistry at Colorado College, and did undergraduate studies in chemistry and biology at Oxford University. He serves on the Board of Directors at Xencor (NASDAQ: XNCR) and Expansion Therapeutics, and Board of Visitors at the Moores Cancer Center at the University of California, San Diego.